PriceTargets.com logo

Tevogen Bio - TVGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.10
  • Forecasted Upside: 560.47%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.08 As of 04/2/2025 11:17 AM ET
▼ -0.015 (-1.38%)

This chart shows the closing price for TVGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
FebMar$1.09Closing price on 04/01/25:
Get New Tevogen Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TVGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TVGN

Analyst Price Target is $7.10
▲ +560.47% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Tevogen Bio in the last 3 months. The average price target is $7.10, with a high forecast of $10.00 and a low forecast of $4.20. The average price target represents a 560.47% upside from the last price of $1.08.

This chart shows the closing price for TVGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/244/254/26$0.18$2.64$5.09$7.55$10Closing price on 04/01/25: $1.09High$10.00Average$7.10Low$4.20




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Tevogen Bio.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/7/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/6/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/2/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/3/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2025

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/11/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/4/2025D. Boral CapitalInitiated CoverageBuy$10.00
6/28/2024Fundamental ResearchSet TargetBuy$4.20
(Data available from 4/2/2020 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 4 very positive mentions
  • 31 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 2 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/2/2025
  • 1 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2025
  • 4 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2025
  • 9 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2025

Current Sentiment

  • 9 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Tevogen Bio logo
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Read More

Today's Range

Now: $1.08
Low: $1.04
High: $1.11

50 Day Range

MA: $1.32
Low: $1.06
High: $1.68

52 Week Range

Now: $1.08
Low: $0.26
High: $4.78

Volume

64,631 shs

Average Volume

5,061,155 shs

Market Capitalization

$188.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Tevogen Bio?

The following Wall Street sell-side analysts have issued research reports on Tevogen Bio in the last year: D. Boral Capital, and Fundamental Research.
View the latest analyst ratings for TVGN.

What is the current price target for Tevogen Bio?

0 Wall Street analysts have set twelve-month price targets for Tevogen Bio in the last year. Their average twelve-month price target is $7.10, suggesting a possible upside of 560.5%. D. Boral Capital has the highest price target set, predicting TVGN will reach $10.00 in the next twelve months. Fundamental Research has the lowest price target set, forecasting a price of $4.20 for Tevogen Bio in the next year.
View the latest price targets for TVGN.

What is the current consensus analyst rating for Tevogen Bio?

Tevogen Bio currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TVGN will outperform the market and that investors should add to their positions of Tevogen Bio.
View the latest ratings for TVGN.

What other companies compete with Tevogen Bio?

Other companies that are similar to Tevogen Bio include Replimune Group, Xencor, Intellia Therapeutics, Anavex Life Sciences and Gyre Therapeutics. Learn More about companies similar to Tevogen Bio.

How do I contact Tevogen Bio's investor relations team?

Tevogen Bio's physical mailing address is 767 THIRD AVENUE 38TH FLOOR, NEW YORK NY, 10017. The company's listed phone number is 913-579-4170 and its investor relations email address is ir@tevogen.com. The official website for Tevogen Bio is www.semperparatusspac.com. Learn More about contacing Tevogen Bio investor relations.